ArticleMethodsX2026
Quantifying uncertainty of tuberculosis drug susceptibility range from single-microplate test.
Article in MethodsX, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The registration of fluorescence intensity converted from resazurin in the course of the respective microtiter assay, as a response to the activity of antibacterial drugs, provides a basis for the quantitative characterisation of their activity. At the same time, this assay operates with relatively small samples, and the studied biochemical process exhibits variability. In this work, we address the question of reporting the minimal inhibitory concentration arguing in favour of its range rather than a single value. To achieve this goal, we propose a method for the combinatorial enhancement of single microplate-based data, followed by non-parametric statistical processing. The approach is illustrated by the case study of ten first- and second-line anti-tuberculosis drugs acting on the standard laboratory strain H37Rv of
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.